ATE205191T1 - Guanidine derivate als inhibitoren des zellulären na+/h+ austauschmechanismus - Google Patents

Guanidine derivate als inhibitoren des zellulären na+/h+ austauschmechanismus

Info

Publication number: ATE205191T1
Authority: AT; Austria
Prior art keywords: hydroxy; pct; hydrogen; protected; inhibitors
Prior art date: 1993-05-17

Application number

AT94914623T

Other languages

English (en)

Inventor

Atsushi Kuno

Yoshikazu Inoue

Hisashi Takasugi

Hiroaki Mizuno

Kumi Yamasaki

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-17

Filing date

1994-05-12

Publication date

2001-09-15

1993-05-17 Priority claimed from GB939310074A external-priority patent/GB9310074D0/en

1993-12-10 Priority claimed from GB939325268A external-priority patent/GB9325268D0/en

1994-05-12 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205191T1 publication Critical patent/ATE205191T1/de

Links

ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title 1
230000001413 cellular effect Effects 0.000 title 1
229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
150000002431 hydrogen Chemical group 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010038372 Renal arteriosclerosis Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
-1 nitro, hydroxy Chemical group 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
125000003226 pyrazolyl group Chemical group 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000035939 shock Effects 0.000 abstract 1
125000003831 tetrazolyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Compositions Of Macromolecular Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Pyrrole Compounds (AREA)
Filtering Materials (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Furan Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT94914623T 1993-05-17 1994-05-12 Guanidine derivate als inhibitoren des zellulären na+/h+ austauschmechanismus ATE205191T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB939310074A GB9310074D0 (en)	1993-05-17	1993-05-17	Guanidine derivatives
GB939325268A GB9325268D0 (en)	1993-12-10	1993-12-10	Guanidine derivatives
PCT/JP1994/000786 WO1994026709A1 (en)	1993-05-17	1994-05-12	GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS

Publications (1)

Publication Number	Publication Date
ATE205191T1 true ATE205191T1 (de)	2001-09-15

Family

ID=26302902

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94914623T ATE205191T1 (de)	1993-05-17	1994-05-12	Guanidine derivate als inhibitoren des zellulären na+/h+ austauschmechanismus

Country Status (17)

Country	Link
US (1)	US5824691A (de)
EP (1)	EP0699185B1 (de)
JP (1)	JPH08511243A (de)
KR (1)	KR100315759B1 (de)
CN (1)	CN1080257C (de)
AT (1)	ATE205191T1 (de)
AU (1)	AU685457B2 (de)
CA (1)	CA2163004A1 (de)
DE (1)	DE69428198T2 (de)
DK (1)	DK0699185T3 (de)
ES (1)	ES2159558T3 (de)
GR (1)	GR3036549T3 (de)
HU (1)	HUT70206A (de)
IL (1)	IL109570A0 (de)
PT (1)	PT699185E (de)
RU (1)	RU2141946C1 (de)
WO (1)	WO1994026709A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4332384A1 (de) *	1993-09-23	1995-03-30	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten III
IL114670A0 (en) *	1994-08-05	1995-11-27	Fujisawa Pharmaceutical Co	Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
EP0723956B1 (de) *	1995-01-30	1999-10-13	Hoechst Aktiengesellschaft	Basisch-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6057322A (en) *	1995-01-30	2000-05-02	Hoechst Aktiengesellschaft	Basically-substituted benzoylguanidines, a process for preparing them, their use as a medicament or diagnostic agent, and a medicament containing them
US5627193A (en) *	1995-02-09	1997-05-06	Mitsui Toatsu Chemicals, Inc.	Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
EP0765867A1 (de) *	1995-09-27	1997-04-02	Hoechst Aktiengesellschaft	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
DE19540995A1 (de) *	1995-11-03	1997-05-07	Hoechst Ag	Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) *	1995-11-14	1997-05-15	Hoechst Ag	Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316438A1 (en)	1995-11-20	1997-05-26	Hoechst Ag	Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
PL316439A1 (en)	1995-11-20	1997-05-26	Hoechst Ag	Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) *	1995-12-14	1997-06-19	Hoechst Ag	Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
GB9600063D0 (en) *	1996-01-03	1996-03-06	Fujisawa Pharmaceutical Co	Guaridine derivatives
WO1997027183A1 (en) *	1996-01-26	1997-07-31	Fujisawa Pharmaceutical Co., Ltd.	Guanidine derivatives
DE19603425A1 (de) *	1996-01-31	1997-08-07	Hoechst Ag	Substituierte Diaryldicarbonsäure-diguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
NZ314105A (en) *	1996-02-02	1997-12-19	Sumitomo Pharma	Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
DE19608162A1 (de) *	1996-03-04	1997-09-11	Hoechst Ag	Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JPH09291076A (ja) *	1996-04-24	1997-11-11	Sumitomo Pharmaceut Co Ltd	置換グアニジン誘導体およびその製法
DE19621482A1 (de) *	1996-05-29	1997-12-04	Hoechst Ag	Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621483A1 (de) *	1996-05-29	1997-12-04	Hoechst Ag	Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2283404A1 (en) *	1997-03-06	1998-09-11	Jun Sasamori	Cycloalka¬b\|pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same
DE19721031A1 (de) *	1997-05-20	1998-11-26	Bayer Ag	Substituierte Pyridylpyrazole
WO1998055475A1 (en) *	1997-06-02	1998-12-10	Fujisawa Pharmaceutical Co., Ltd.	Guanidine deriviatives as inhibitors of na+/h+ exchange in cells
DE19737224A1 (de) *	1997-08-27	1999-03-18	Hoechst Marion Roussel De Gmbh	Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
CA2321642A1 (en)	1998-02-27	1999-09-02	Ronald T. Wester	N-¬(substituted five-membered di- or triaza diunsaturated ring)carbonyl\|guanidine derivatives for the treatment of ischemia
HK1040510A1 (en) *	1999-05-17	2002-06-14	Teijin Limited	Cyanobiphenyl derivatives
US6734205B2 (en)	1999-12-16	2004-05-11	Sumitomo Pharmaceuticals Company Limited	Substituted guanidine derivatives
DE10024319A1 (de) *	2000-05-17	2001-11-22	Merck Patent Gmbh	Bisacylguanidine
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
DE10061876A1 (de) *	2000-12-12	2002-06-20	Aventis Pharma Gmbh	Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
KR20040019043A (ko) *	2001-07-30	2004-03-04	닥터 레디스 레보러터리즈 리미티드	아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
FR2842524B1 (fr)	2002-07-16	2005-04-22	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
AU2003294275A1 (en) *	2002-11-21	2004-06-18	New York Blood Center	Compounds for inhibition of hiv infection by blocking hiv entry
DE60329030D1 (de) *	2002-12-04	2009-10-08	Ore Pharmaceuticals Inc	Melanocortin-rezeptormodulatoren
MXPA05011840A (es) *	2003-05-06	2006-01-26	Merck Patent Gmbh	Procedimiento para cristalizar sales de guanidinio.
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
AU2013205388B2 (en) *	2005-06-24	2016-05-05	Biotron Limited	Antiviral compounds and methods
NZ610715A (en)	2005-06-24	2014-07-25	Biotron Ltd	Antiviral compounds and methods
CN100371328C (zh) *	2006-01-19	2008-02-27	中国药科大学	取代苯甲酰基胍衍生物、其制备方法及其医药用途
ES2596706T3 (es) *	2006-06-29	2017-01-11	F. Hoffmann-La Roche Ag	Arilamidas con sustitución de tetrazol
CN101679244B (zh)	2007-04-11	2014-01-01	橘生药品工业株式会社	5元杂环衍生物及其医药用途
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
MX2010003156A (es) *	2007-10-04	2010-04-01	Hoffmann La Roche	Derivados de aril amida substituida con tetrazol y usos de los mismos.
HRP20130614T1 (en)	2007-12-17	2013-08-31	F. Hoffmann - La Roche Ag	Novel pyrazole-substituted arylamides
CA2708791C (en)	2007-12-17	2016-06-21	F. Hoffmann-La Roche Ag	Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists
ES2542245T3 (es)	2007-12-17	2015-08-03	F. Hoffmann-La Roche Ag	Derivados de arilamida sustituido con triazol y su utilización como antagonistas del receptor purinérgico P2x3 y/o P2x2/3
AU2008337665B2 (en)	2007-12-17	2014-01-16	F. Hoffmann-La Roche Ag	Tetrazole-substituted arylamide derivatives and their use as P2x3 and/or P2x2/3 purinergic receptor antagonists
KR101766619B1 (ko)	2008-12-31	2017-08-08	알데릭스, 인코포레이티드	체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en)	2017-01-09	2018-07-12	Ardelyx, Inc.	Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20120015355A (ko)	2009-05-29	2012-02-21	글락소스미스클라인 엘엘씨	트롬보포이에틴 효능제 화합물의 투여 방법
SG177301A1 (en)	2009-06-22	2012-02-28	Hoffmann La Roche	Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
WO2010149578A2 (en)	2009-06-22	2010-12-29	F. Hoffmann-La Roche Ag	Novel biphenyl and phenyl-pyridine amides
ES2593405T3 (es)	2009-06-22	2016-12-09	F. Hoffmann-La Roche Ag	Nuevas arilamidas sustituidas por benzoxazolona
US9090584B2 (en)	2010-01-26	2015-07-28	Allergan, Inc.	Therapeutic agents for treatment of ocular hypertension
US10376481B2 (en)	2012-08-21	2019-08-13	Ardelyx, Inc.	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
HK1211469A1 (en)	2012-08-21	2016-05-27	Ardelyx, Inc.	Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014250956B2 (en)	2013-04-12	2019-04-04	Ardelyx, Inc.	NHE3-binding compounds and methods for inhibiting phosphate transport
BR112019013963A2 (pt)	2017-01-09	2020-04-28	Ardelyx Inc	inibidores de antiporte mediado por nhe
KR102669987B1 (ko)	2017-01-09	2024-05-31	알데릭스, 인코포레이티드	위장관 장애를 치료하는 데 유용한 화합물
IL306058A (en)	2017-08-04	2023-11-01	Ardelyx Inc	History of glycyrrhizinic acid for the treatment of excess potassium in the blood
TWI861053B (zh)	2019-02-07	2024-11-11	美商阿德利克斯公司	用於治療高鉀血症之化合物及方法
CN114340631A (zh)	2019-05-21	2022-04-12	阿德利克斯股份有限公司	用于降低患者的血清磷酸盐的组合
CN113527672B (zh) *	2020-03-30	2022-09-20	复旦大学	一种胍基衍生物及其基因递释系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1619538B1 (de) *	1967-08-04	1971-06-24	Bayer Ag	Verfahren zum Färben von Fasermaterialien aus Polyacrylnitril oder acrylnitrilhaltigen Mischpolymerisaten
US4251545A (en) *	1979-09-19	1981-02-17	Gaf Corporation	Fungicidal process using 1-(alkoxyaroyl)guanidines
ATE24997T1 (de) *	1982-01-04	1987-02-15	Karl H Beyer Jr	Hyperueretische mittel.
JPS59106993A (ja) *	1982-12-10	1984-06-20	Ricoh Co Ltd	ジアゾ系感熱記録材料
TW213903B (de) *	1991-08-16	1993-10-01	Boehringer Ingelheim Kg
DE59302959D1 (de) *	1992-02-15	1996-07-25	Hoechst Ag	3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
CZ284456B6 (cs) *	1992-02-15	1998-12-16	Hoechst Aktiengesellschaft	Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DK0556673T3 (da) *	1992-02-15	1998-04-14	Hoechst Ag	o-Substituerede benzoylguanidiner til behandling og profylakse af hjerterytmeforstyrrelser og iskæmisk inducerede skader samt til inhiberering af celleproliferation
EP0577024B1 (de) *	1992-07-01	1996-10-16	Hoechst Aktiengesellschaft	3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0603650B1 (de) *	1992-12-16	1997-04-02	Hoechst Aktiengesellschaft	3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE59403818D1 (de) *	1993-02-20	1997-10-02	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
DE4318658A1 (de) *	1993-06-04	1994-12-08	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) *	1993-06-05	1994-12-08	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) *	1993-07-31	1995-02-02	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4327244A1 (de) *	1993-08-13	1995-02-16	Hoechst Ag	Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4328869A1 (de) *	1993-08-27	1995-03-02	Hoechst Ag	Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

1994
- 1994-05-05 IL IL10957094A patent/IL109570A0/xx unknown
- 1994-05-12 AU AU66912/94A patent/AU685457B2/en not_active Ceased
- 1994-05-12 EP EP94914623A patent/EP0699185B1/de not_active Expired - Lifetime
- 1994-05-12 PT PT94914623T patent/PT699185E/pt unknown
- 1994-05-12 US US08/532,804 patent/US5824691A/en not_active Expired - Fee Related
- 1994-05-12 CN CN94192121A patent/CN1080257C/zh not_active Expired - Fee Related
- 1994-05-12 KR KR1019950704730A patent/KR100315759B1/ko not_active Expired - Fee Related
- 1994-05-12 HU HU9403233A patent/HUT70206A/hu unknown
- 1994-05-12 RU RU95122558A patent/RU2141946C1/ru active
- 1994-05-12 ES ES94914623T patent/ES2159558T3/es not_active Expired - Lifetime
- 1994-05-12 AT AT94914623T patent/ATE205191T1/de not_active IP Right Cessation
- 1994-05-12 WO PCT/JP1994/000786 patent/WO1994026709A1/en not_active Ceased
- 1994-05-12 DK DK94914623T patent/DK0699185T3/da active
- 1994-05-12 DE DE69428198T patent/DE69428198T2/de not_active Expired - Fee Related
- 1994-05-12 JP JP6525245A patent/JPH08511243A/ja active Pending
- 1994-05-12 CA CA002163004A patent/CA2163004A1/en not_active Abandoned
2001
- 2001-09-06 GR GR20010401402T patent/GR3036549T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5824691A (en)	1998-10-20
DK0699185T3 (da)	2001-11-12
JPH08511243A (ja)	1996-11-26
HUT70206A (en)	1995-09-28
CN1080257C (zh)	2002-03-06
DE69428198T2 (de)	2002-03-28
KR100315759B1 (ko)	2002-04-06
WO1994026709A1 (en)	1994-11-24
RU2141946C1 (ru)	1999-11-27
GR3036549T3 (en)	2001-12-31
AU6691294A (en)	1994-12-12
ES2159558T3 (es)	2001-10-16
CA2163004A1 (en)	1994-11-24
EP0699185B1 (de)	2001-09-05
PT699185E (pt)	2002-01-30
IL109570A0 (en)	1994-08-26
EP0699185A1 (de)	1996-03-06
AU685457B2 (en)	1998-01-22
CN1123545A (zh)	1996-05-29
DE69428198D1 (de)	2001-10-11
KR960701841A (ko)	1996-03-28

Legal Events

Date	Code	Title	Description
2005-02-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE205191T1 (de)	2001-09-15	Guanidine derivate als inhibitoren des zellulären na+/h+ austauschmechanismus
PT686156E (pt)	2002-12-31	Pirazolitriazinas com actividade inibidora de interleucina-1 e factor de necrose de tumor
DE60111205D1 (de)	2005-07-07	Triarylimidazol-derivate als cytokin-inhibitoren
ATE231143T1 (de)	2003-02-15	Triarylimidazole
NZ502370A (en)	2002-10-25	Guanidine mimics for use as factor Xa inhibitors
PH31122A (en)	1998-02-23	Nitrogen-containing fused-heterocycle compounds.
DE69316224D1 (de)	1998-02-12	Chinuclidine derivate als squalen synthase inhibitoren
PT892793E (pt)	2003-08-29	Derivados 2-cianoiminoimidazolo inibidores da pde iv
DE60112306D1 (de)	2005-09-01	Kondensierte pyrazindionderivate als pde5 inhibitore
DE69401584D1 (de)	1997-03-06	Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese
GB9305641D0 (en)	1993-05-05	Therapeutic agents
PT1189923E (pt)	2005-05-31	Derivados aromaticos e heterociclicos de fitosterois e/ ou fitostanois para utilizacao no tratamento ou prevencao de doenca cardiovascular
HUP0103303A2 (hu)	2002-04-29	Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB9313330D0 (en)	1993-08-11	New compound and its preparation
NO20022123L (no)	2002-05-03	Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
MXPA03004023A (es)	2004-02-12	Compuestos quimicos.
DE69413831D1 (de)	1998-11-12	Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
MXPA03000887A (es)	2004-04-05	Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
DE69314649D1 (de)	1997-11-20	Chinuclidine derivate als squalen synthase inhibitoren
ATE255102T1 (de)	2003-12-15	Benzothiophenderivate, ihre herstellung und verwendung als urokinase-inhibitoren
TW289019B (de)	1996-10-21